Pluri (NASDAQ:PLUR) Posts Quarterly Earnings Results

Pluri (NASDAQ:PLUR) released its quarterly earnings data on Thursday. The company reported ($0.71) EPS for the quarter, Zacks reports.

Pluri Stock Down 5.1%

Shares of NASDAQ PLUR traded down $0.19 during mid-day trading on Thursday, hitting $3.55. 16,305 shares of the company were exchanged, compared to its average volume of 11,817. The firm has a market cap of $35.43 million, a price-to-earnings ratio of -0.75 and a beta of 0.67. The stock has a 50 day simple moving average of $3.24 and a 200-day simple moving average of $4.02. Pluri has a 1-year low of $2.82 and a 1-year high of $7.13.

Institutional Trading of Pluri

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC purchased a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri as of its most recent SEC filing. Institutional investors own 16.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pluri in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $12.00.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.